GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nirvana Life Sciences Inc (XCNQ:NIRV) » Definitions » Debt-to-Asset

Nirvana Life Sciences (XCNQ:NIRV) Debt-to-Asset : 0.11 (As of Jan. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Nirvana Life Sciences Debt-to-Asset?

Nirvana Life Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$0.02 Mil. Nirvana Life Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$0.00 Mil. Nirvana Life Sciences's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jan. 2024 was C$0.21 Mil. Nirvana Life Sciences's debt to asset for the quarter that ended in Jan. 2024 was 0.11.


Nirvana Life Sciences Debt-to-Asset Historical Data

The historical data trend for Nirvana Life Sciences's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nirvana Life Sciences Debt-to-Asset Chart

Nirvana Life Sciences Annual Data
Trend Oct18 Oct19 Oct20 Oct21 Apr22 Apr23
Debt-to-Asset
Get a 7-Day Free Trial 81.00 13.50 - - 0.84

Nirvana Life Sciences Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 0.84 0.09 0.36 0.11

Competitive Comparison of Nirvana Life Sciences's Debt-to-Asset

For the Biotechnology subindustry, Nirvana Life Sciences's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nirvana Life Sciences's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nirvana Life Sciences's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Nirvana Life Sciences's Debt-to-Asset falls into.



Nirvana Life Sciences Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Nirvana Life Sciences's Debt-to-Asset for the fiscal year that ended in Apr. 2023 is calculated as

Nirvana Life Sciences's Debt-to-Asset for the quarter that ended in Jan. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nirvana Life Sciences  (XCNQ:NIRV) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Nirvana Life Sciences Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Nirvana Life Sciences's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Nirvana Life Sciences (XCNQ:NIRV) Business Description

Traded in Other Exchanges
N/A
Address
650 West Georgia Street, Suite 2110, Vancouver, BC, CAN, V6B 4N8
Nirvana Life Sciences Inc is focused on developing medical products and regimens that address addiction. The company is working on novel formulations of psilocybin and other naturally-sourced psychedelics to treat pain, opioid dependency, and other health problems.

Nirvana Life Sciences (XCNQ:NIRV) Headlines

No Headlines